

Jana Fassunke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410982/publications.pdf>

Version: 2024-02-01

23
papers

1,098
citations

840776

11
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

2323
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer, 2014, 14, 13.	2.6	220
2	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	1.1	178
3	<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. Clinical Cancer Research, 2015, 21, 907-915.	7.0	155
4	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. Journal of Thoracic Oncology, 2015, 10, 1049-1057.	1.1	85
5	<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget, 2015, 6, 10577-10585.	1.8	85
6	miRNAâ€221 and miRNAâ€222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Molecular Oncology, 2015, 9, 1421-1433.	4.6	71
7	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. Journal of Thoracic Oncology, 2016, 11, 122-127.	1.1	65
8	Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing. Journal of Molecular Diagnostics, 2017, 19, 801-804.	2.8	64
9	Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics. PLoS ONE, 2014, 9, e104566.	2.5	46
10	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 509-520.	2.8	29
11	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
12	Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue. International Journal of Molecular Medicine, 2015, 36, 1233-1243.	4.0	12
13	Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. Experimental and Molecular Pathology, 2015, 99, 682-686.	2.1	12
14	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 102.	5.4	11
15	Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. Lung Cancer, 2020, 144, 40-48.	2.0	9
16	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. BMC Cancer, 2015, 15, 291.	2.6	7
17	Bronchoscopic Brushing from Central Lung Cancerâ€”Next Generation Sequencing Results are Reliable. Lung, 2019, 197, 333-337.	3.3	7
18	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. Lung Cancer, 2022, 168, 10-20.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence. <i>Lung Cancer</i> , 2021, 151, 91-96.	2.0	5
20	Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20682-e20682.	1.6	2
21	Molecular Diagnostics of Lung Cancer in Serous Effusion Samples. <i>Journal of Molecular Pathology</i> , 2022, 3, 78-87.	1.2	2
22	EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20577-e20577.	1.6	1
23	Combining biopsy tools improves mutation detection rate in central lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00002-2020.	2.6	0